AstraZeneca’s Checkpoint Inhibitor Imfinzi Flops in Cervical Cancer Trial
AstraZeneca’s checkpoint inhibitor Imfinzi (durvalumab) didn’t meet its primary endpoint of improving progression-free survival when compared with chemoradiotherapy (CRT) alone in the treatment of patients with locally advanced cervical cancer,…